Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bridger

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclamsG J Bridger, R T Skerlj, S Padmanabhan, et al.
Inorganic Chemistry|March 18, 2003
Ruthenium(III) polyaminocarboxylate complexes: efficient and effective nitric oxide scavengersBeth R Cameron, Marilyn C Darkes, Helen Yee, et al.
Journal of the American Chemical Society|September 28, 2011
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approachMarkus Metz, Elyse Bourque, Jean Labrecque, et al.
Virology|March 11, 2011
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assayJean Labrecque, Markus Metz, Gloria Lau, et al.
Journal of Medicinal Chemistry|January 2, 2010
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replicationGary J Bridger, Renato T Skerlj, Pedro E Hernandez-Abad, et al.
Journal of Medicinal Chemistry|March 20, 2010
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replicationRenato T Skerlj, Gary J Bridger, Al Kaller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
Biochemical Pharmacology|December 8, 2011
The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitorRenee M Mosi, Virginia Anastassova, Jennifer Cox, et al.
Biochemical Pharmacology|June 23, 2009
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4Veronique Bodart, Virginia Anastassov, Marilyn C Darkes, et al.
Berliner Und Munchener Tierarztliche Wochenschrift|October 30, 2009
Neonatal health in calves--comprehensive solutions for complex enteric disordersB Makoschey, W Klee, V Martella, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|January 5, 1996
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. 2. Effect of heteroaromatic linkers on the activity of bicyclamsG J Bridger, R T Skerlj, S Padmanabhan, et al.
Inorganic Chemistry|March 18, 2003
Ruthenium(III) polyaminocarboxylate complexes: efficient and effective nitric oxide scavengersBeth R Cameron, Marilyn C Darkes, Helen Yee, et al.
Journal of the American Chemical Society|September 28, 2011
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approachMarkus Metz, Elyse Bourque, Jean Labrecque, et al.
Virology|March 11, 2011
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assayJean Labrecque, Markus Metz, Gloria Lau, et al.
Journal of Medicinal Chemistry|January 2, 2010
Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replicationGary J Bridger, Renato T Skerlj, Pedro E Hernandez-Abad, et al.
Journal of Medicinal Chemistry|March 20, 2010
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replicationRenato T Skerlj, Gary J Bridger, Al Kaller, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 24, 2004
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix, Ann C Collier, Michael M Lederman, et al.
Biochemical Pharmacology|December 8, 2011
The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitorRenee M Mosi, Virginia Anastassova, Jennifer Cox, et al.
Biochemical Pharmacology|June 23, 2009
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4Veronique Bodart, Virginia Anastassov, Marilyn C Darkes, et al.
Berliner Und Munchener Tierarztliche Wochenschrift|October 30, 2009
Neonatal health in calves--comprehensive solutions for complex enteric disordersB Makoschey, W Klee, V Martella, et al.
Pageof 7